Tercica, Inc. Announces Results from Increlex® IGFD Patient Registry and Other Increlex® Studies at the 90th Meeting of the Endocrine Society
Published: Jun 16, 2008
BRISBANE, Calif.--(BUSINESS WIRE)--Tercica, Inc. (NASDAQ: TRCA) today announced the first results from the Increlex® Growth Forum Database (IGFD) Registry in two posters presented at the 90th annual meeting of the Endocrine Society in San Francisco. Increlex® (mecasermin (rDNA origin) injection) is currently approved in the United States for the treatment of severe Primary IGF-1 Deficiency.